rss
Br J Ophthalmol 2005;89:1407-1409 doi:10.1136/bjo.2005.072678
  • Clinical science
    • Scientific reports

Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease

  1. M Kitamura1,4,
  2. N Kitaichi1,
  3. M Takeuchi2,
  4. H Kitamei1,4,
  5. K Namba1,
  6. S-i Yamagishi3,
  7. K Iwabuchi4,
  8. K Onoé4,
  9. S Ohno1
  1. 1Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  2. 2Department of Pathophysiological Science, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan
  3. 3Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan
  4. 4Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
  1. Correspondence to: Mizuki Kitamura MD, Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan; mizukita825ybb.ne.jp
  • Accepted 1 July 2005

Abstract

Background/aims: Advanced glycation end products (AGEs) are considered to act as mediators of both age related pathologies and diabetic complications. It was recently reported that glyceraldehyde derived AGE (AGE-2) has a strong biological effect on various diseases. The aim of this study was to investigate the serum AGE-2 levels in Vogt-Koyanagi-Harada (VKH) disease.

Methods: Sera were obtained from 31 patients with active VKH. 20 of these 31 patients were treated with systemic corticosteroids. As controls, 33 healthy volunteers were also examined. The serum AGE-2 levels were determined with a competitive enzyme linked immunosorbent assay using AGE-2 polyclonal antibody.

Results: The mean AGE-2 level in the sera of patients with VKH disease was 4.91 (SD 2.23) U/ml, which was significantly lower than that of the healthy control subjects (8.32 (2.94), p<0.001). The average serum AGE-2 level significantly increased to 13.49 (2.17) U/ml after the patients were treated with systemic corticosteroids (p<0.001).

Conclusions: These results suggest that AGE-2 may be involved in the onset of VKH disease.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.